Comprehensive studies reporting metabolic changes with respect to mutIDH have mainly focused on glioma, despite the availability of cell lines with stable mutIDH1/2 expression for several other cancers with high rates of IDH1/2 mutations; e.g., AML, chondrosarcoma, and ICC. This evidence concerns the gene IDH1 and central nervous system cancer.